Cargando…

Comedication and Treatment Length in Users of Acetylcholinesterase Inhibitors

BACKGROUND/AIMS: Reduced clinical effect on cognitive decline in dementia by acetylcholinesterase inhibitors (AChEIs) may be due to concurrent use of drugs with anticholinergic properties. The aim was to analyze the incidence of AChEI use and comedication with drugs with anticholinergic properties a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sverdrup Efjestad, Anne, Ihle-Hansen, Hege, Hjellvik, Vidar, Blix, Hege Salvesen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346931/
https://www.ncbi.nlm.nih.gov/pubmed/28413414
http://dx.doi.org/10.1159/000454948
Descripción
Sumario:BACKGROUND/AIMS: Reduced clinical effect on cognitive decline in dementia by acetylcholinesterase inhibitors (AChEIs) may be due to concurrent use of drugs with anticholinergic properties. The aim was to analyze the incidence of AChEI use and comedication with drugs with anticholinergic properties and other potential unfavorable effects. METHODS: A prospective study applying drug use data from the Norwegian Prescription Database. Anticholinergic Drug Scale (ADS) scores were used as a measure of overall anticholinergic burden. RESULTS: Patients with high ADS scores were more frequently discontinuing treatment early. Coprescribing of antipsychotics was strongly associated with early discontinuation of AChEI treatment. CONCLUSION: Coprescribing with potentially unfavorable medications was common. A high ADS score was associated with early discontinuation of treatment.